December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Overuse of black box warnings is scare tactic
May 1st 2005As the Vioxx/Celebrex scandal lays waste to the American healthcare landscape as we know it, the U.S. Food and Drug Administration (FDA) finds itself under relentless pressure to get things right. Congress is demanding more stringent safety standards and even threatening to create a new federal agency to take safety approvals and monitoring out of the FDA's hands.
Candida antifungal performs well in study
April 1st 2005An investigational topical antifungal product containing miconazole nitrate 0.25 percent in a petrolatum/zinc oxide barrier ointment base (Zimycan, Barrier Therapeutics) has demonstrated positive efficacy and safety results in a phase 3 study of the treatment of Candida diaper dermatitis.
Testing identifies key culprits in ACD
April 1st 2005Miami — Bacitracin has been labeled a top cause of allergic contact dermatitis (ACD) in children. Notably, it is an ingredient in Neosporin (Pfizer) and a staple in first aid kits in schools, summer camps and just about every other child-centered environment. Yet private practitioners do not routinely test for this allergen.
Mastocytosis: Be alert to vague symptoms
April 1st 2005Loma Linda, Calif. — Dermatologists don't discuss mastocytosis much because it is rare and confusing, but, in large metropolitan areas, the incidence rate can add up to many patients, says Linda Golkar, M.D., assistant professor of dermatology, Loma Linda University, Loma Linda, Calif. Learning when to consider the disease, what diagnostic tests to perform and how to exclude involvement of other organs are required skills for front-line treatment.
Superficial peds infections abound
April 1st 2005New Orleans - In today's global, transient and sometimes overcrowded society, the spread of superficial cutaneous infections and infestations in children appears to be even more common than previously thought. International travel, immigration and foreign adoption have altered the typical distribution of some pediatric infections and infestations.
Advances aid treatment in pediatric dermatology
April 1st 2005There have been a number of important advances in pediatric dermatology, ranging from finding the optimal use for tissue adhesives to gaining a better understanding of general and local anesthetic use in the pediatric population and a greater appreciation for dermatologic surgeons' roles in treating vascular lesions and birthmarks.
Accurate, timely diagnosis of dermatoses in children critical
April 1st 2005New Orleans — Rare, life-threatening dermatoses are presenting in pediatric patients across the country, and some dermatologists are missing these critical diagnoses, according to Patricia Treadwell, M.D., professor of pediatrics, Riley Hospital for Children, Indianapolis.
Add gusto to medical presentations
April 1st 2005New Orleans — Being a respected authority doesn't guarantee that one's presentations will stand out. Achieving this goal requires speakers to select subjects they love while knowing themselves and their audience, says Steven K. Shama, M.D., M.P.H., inprivate practice in Brookline, Mass.
Modern medical acupuncture in dermatology
April 1st 2005New Orleans — Modern medical acupuncture can be used in conjunction with current Western treatments in dermatology to optimize patient outcome, according to Donald J. Baker, M.D., clinical professor and director of integrative dermatology at the University of Medicine and Dentistry, New Jersey, Robert Wood Johnson Medical School, Camden, N.J.
Food-related atopic dermatitis may predict childhood asthma
April 1st 2005Boston — According to Hugh A.Sampson, knowing there is a higher incidence of asthma among children who develop atopic dermatitis (AD) and food allergy early in life makes it possible to identify those who are likely to develop the respiratory disorder.
WDS: Small organization, big contribution
April 1st 2005I just ended one of the best years of my life! And one of its best aspects was experiencing the value of smaller organizations within our larger dermatology community. In particular, I want to share my perceptions of the Women's Dermatologic Society (WDS), of which I am the immediate past president, and show how it continues to add significantly to the greater whole.
FDA board to protect patients, update docs
April 1st 2005Washington — Scorched by controversy over how it approves prescription drugs for the marketplace, the U.S. Food and Drug Administration (FDA) is preparing to establish an independent Drug Safety Oversight Board (DSB) to monitor FDA-approved pharmaceuticals and update physicians and patients when new information becomes available.
Paradigm shift in Rosacea therapy
March 1st 2005Las Vegas — With recent modifications to the rosacea classification system and a greater understanding of the use of antibiotics as inflammatory mediators in rosacea treatment, Joseph Bikowski, M.D. of the Bikowski Skin Care Center, Sewickley, Pa., outlined a tiered approach to rosacea treatment at the Winter Dermatology Conference here.
Various treatments help chronic hand dermatitis
March 1st 2005Aruba — Though its impact can be socially and financially crippling, chronic allergic contact dermatitis (ACD) of the hand responds to aggressive drug therapies combined with on-the-job precautions, according to Donald V. Belsito, M.D., M.B.A., professor and director of dermatology, University of Kansas Medical Center.
Try to differentiate hand eczema variants
March 1st 2005New Orleans — Hand eczema is one of the most common work-related illnesses or diseases. But diagnosis is complicated because hand eczema is almost always a group of concurrent reactions (to irritants, allergens and friction) that is exacerbated by the use of water, according to Frances J. Storrs, M.D., professor emerita of dermatology, Oregon Health and Science University in Portland.
Calcineurin inhibitors demonstrate versatility
March 1st 2005Aruba — Along with improved safety over topical steroids, calcineurin inhibitors appear to offer relief for a variety of skin conditions including pruritus and psoriasis, especially in sensitive areas, according to Joseph F. Fowler, Jr., M.D., clinical professor, University of Louisville"s Division of Dermatology.
Media microscope analyzes misuse of topicals
March 1st 2005New Orleans — Recent headlines underscore the life-threatening dangers of topical medications — information that may shock the lay community. Dermatologists should take into account the well-known risks to internal organ systems that these drugs present, according to Peter J. Aronson, M.D.